Meeting
2023 ASCO Annual Meeting
Active bone marrow-sparing to reduce the incidence of grade 3+ acute hematologic toxicity in patients with locally advanced cervical cancer who receive chemoradiotherapy: A single-center prospective randomized controlled trial.
Authors
ShanBing Wang
Department of Oncology, the Second People's Hospital of Yibin City, Yibin, Sichuan, China
ShanBing Wang , JiaPei Liu , Kaijian Lei
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Biologic Correlates
Clinical Trial Registration Number
ChiCTR-IOR-16010214
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5524)
DOI
10.1200/JCO.2023.41.16_suppl.5524
Abstract #
5524
Poster Bd #
219
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
SPECT-defined, active bone marrow–sparing, volumetric-modulated arc therapy reduces the incidence of acute hematologic toxicity in patients with locally advanced cervical cancer who receive chemoradiotherapy.
First Author: Shan Bing Wang
Poster
2021 ASCO Annual Meeting
Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).
First Author: John M. Varlotto
Poster
2018 ASCO Annual Meeting
Neoadjuvant chemotherapy with cisplatin and gemcitabine followed by chemoradiation with cisplatin in locally advanced cervical cancer: A phase II, prospective, randomized, trial.
First Author: Samantha Silva
Poster
2011 ASCO Annual Meeting
Phase II study of chemoradiation plus bevacizumab (BV) for locally/regionally advanced nasopharyngeal carcinoma (NPC): Preliminary clinical results of RTOG 0615.
First Author: N. Y. Lee